MedTrace Logo

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

NCT06978660 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-03-16

No results posted yet for this study

Summary

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.

Conditions

  • Transthyretin Cardiac Amyloidosis

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Idoven 1903 S.L.

    lead INDUSTRY

Principal Investigators

  • Pablo García Pavía, MD, PhD · Hospital Universitario Puerta de Hierro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06978660 on ClinicalTrials.gov